Matthew Angel - 24 Mar 2026 Form 4 Insider Report for Tempest Therapeutics, Inc. (TPST)

Reporting relationship: CEO and President, Director, 10%+ Owner
Issuer ticker: TPST
Reported as of: 24 Mar 2026
Net transaction value: +$500,001
SEC form: 4
Accepted by SEC: 25 Mar 2026, 17:32:36 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Angel

Key filing fact

Matthew Angel filed Form 4 for Tempest Therapeutics, Inc. (TPST) on 25 Mar 2026.

Key facts

This page summarizes Matthew Angel's Form 4 filing for Tempest Therapeutics, Inc. (TPST).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Mar 2026, 17:32.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: +$500,001.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001931356 Primary reporting owner

Angel Matthew

Relationship: CEO and President, Director, 10%+ Owner
Address: C/O TEMPEST THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE
Signature: /s/ Matthew Angel
Signature date: 25 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TPST transaction

Common Stock

Purchase

Transaction value: $500,001
Shares: +231,482
Change %
Price: $2.16
Shares after: 231,482
Date: 24 Mar 2026
Ownership: By Factor Bioscience Inc.
Footnotes: F1

TPST holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,837,070
Date: 24 Mar 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares are held by Factor Bioscience Inc. ("Factor"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Footnote F2

The shares reported herein give effect to the pro rata distributions of shares by Erigen LLC for no additional consideration to its members, subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form the Reporting Person's ownership in such shares, the Reporting Person was not required to report the distribution pursuant to Section 16.